Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

Exclusion Criteria

• •Patients must have completed definitive breast surgery including total mastectomy and axillary dissection (modified radical mastectomy), total mastectomy and sentinel node biopsy, lumpectomy and axillary dissection, or lumpectomy and sentinel node biopsy; NOTE: axillary dissection is strongly encouraged in patients with lymph node involvement identified on sentinel node biopsy
• •Margins of lumpectomy or mastectomy must be histologically free of invasive breast cancer and ductal carcinoma in situ (DCIS); patients with resection margins positive for lobular carcinoma in situ (LCIS) are eligible
• •(ARM A ONLY) Interval between last surgery for breast cancer (lumpectomy, mastectomy, sentinel node biopsy, axillary dissection or re-excision of lumpectomy margins) and D1 must be \> 28 days and =\< 84 days
• •ECOG performance status of 0-2
• •Absolute neutrophil count \>= 1000/mm\^3
• •Platelet count \>= 100,000/mm\^3
• •Total bilirubin =\< 1.5 mg/dL
• •AST =\< 2 upper limit of normal
• •Serum creatinine =\< 1.5 mg/dL
• •Urine protein: creatinine ratio \< 1.0
• •PT INR =\< 1.5
• •PTT =\< 1.5 x normal
• •LVEF \>= institutional limits of normal by MUGA or ECHO
• •Prior to registration the investigator must specify if radiation is planned; patients who have undergone a lumpectomy must receive radiation; post-mastectomy radiation is at the investigator's discretion
• •Patients must not have a non-healing wound or fracture; patients with an abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months are excluded
• •Patients must not have hypersensitivity to paclitaxel or drugs using the vehicle Cremophor, Chinese hamster ovary cell products or other recombinant human antibodies
• •Patients who have experienced myocardial infarction or unstable angina within 12 months are excluded
• •Patients who have had experienced an arterial thrombotic event within 12 months are excluded
• •Patients must not have uncontrolled or clinical significant arrhythmia
• •Women must not be pregnant or breast-feeding due to the potential harmful effects of bevacizumab on the developing fetus; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy
• •Women of childbearing potential and sexually active males are required to use an accepted and effective method of contraception while on study and for at least 3-4 months after the last dose of bevacizumab